RxDoctor Payments Data

Drew Triplett, DO

Gastroenterology · Dayton, OHNPI 1255674966

Payments from drug & device makers

$44,644in general payments, 2019–2025

Across 192 payments — averaging $232.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$37K
  • Olympus Corporation Of The Americas$3K
  • Boston Scientific$2K
  • AbbVie$941
  • QOL Medical, LLC$202
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$199
  • plus $1K from 20 others
$388in research payments, 2019–2025

Across 1 payment — averaging $388.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$388

What the payments were for

  • Travel & lodging$5,10563%
  • Food & beverage$2,98837%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,644 in reported general payments places this provider in the 80th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$144,325
Medicare patients
281
Services billed
3,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide31$19,006
ClenpiqSod Picosulf/Mag Ox/Citric Ac66$11,207
Mesalamine11$5,849
Sucralfate26$3,639
Ursodiol12$3,077
Omeprazole264$2,715
Pantoprazole Sodium134$1,917
Colestipol Hcl30$1,439
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates20$1,062
Dicyclomine Hcl54$943
LoperamideLoperamide Hcl11$639
Azathioprine14$507
Esomeprazole Magnesium19$478
Entecavir11$405
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$941$19,00631 claims
Ferring Pharmaceuticals Inc.Clenpiq$12$11,20766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →